Diet

The Breakthrough Institute Endorses the EMIT LESS Act, A Step Toward Reducing Enteric Methane Emissions

Retrieved on: 
Thursday, March 28, 2024

Targeting enteric fermentation in livestock production represents an opportunity to curb nearly one-quarter of U.S. methane emissions.

Key Points: 
  • Targeting enteric fermentation in livestock production represents an opportunity to curb nearly one-quarter of U.S. methane emissions.
  • Reducing enteric methane emissions can be both a climate win, and an economic imperative by reducing the cost of cattle feed.
  • The legislation directs the U.S. Department of Agriculture (USDA) to expand domestic capacity to develop and increase the adoption of enteric methane solutions.
  • Furthermore, the bill would make enteric methane reduction products and practices eligible for cost-share under several USDA conservation programs.

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024

“We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.

Key Points: 
  • “We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.
  • “There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss.
  • Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at week 48, with weight loss continuing at the end of treatment.
  • Financial Results for the Three Months Ended December 31, 2023
    Altimmune had cash, cash equivalents and short-term investments totaling $198.0 million at December 31, 2023.

Filippo Berio announces exclusive partnership with Alzheimer's Drug Discovery Foundation, supporting critical research and brain health

Retrieved on: 
Monday, April 8, 2024

LYNDHURST, N.J., April 8, 2024 /PRNewswire/ -- Filippo Berio, one of the nation's top-selling and longstanding olive oil brands, has established an exclusive partnership with the Alzheimer's Drug Discovery Foundation to raise awareness for Alzheimer's disease and contribute crucial funds to support groundbreaking research aimed at finding a cure for Alzheimer's and related dementias. The collaboration is a natural fit, given the growing body of research that indicates properties in olive oil may not only play a pivotal role in cardiovascular health but also provide important benefits to brain health. The partnership aims to increase overall awareness of lifestyle changes, including a healthy diet, that may positively affect brain health, which can help consumers to make healthier, informed choices.

Key Points: 
  • The collaboration is a natural fit, given the growing body of research that indicates properties in olive oil may not only play a pivotal role in cardiovascular health but also provide important benefits to brain health.
  • The partnership aims to increase overall awareness of lifestyle changes, including a healthy diet, that may positively affect brain health, which can help consumers to make healthier, informed choices.
  • Studies indicate that consuming olive oil may have protective effects on the brain and reduce the risk of Alzheimer's."
  • This will be the second consecutive year Filippo Berio is supporting one of the ADDF's signature fundraising events.

Premium Jane Introduces Innovative Keto Product Line to Enhance Ketogenic Diet Experience

Retrieved on: 
Monday, April 8, 2024

The cornerstone of Premium Jane's new Keto line is a once-a-day fiber supplement formulated with inulin and chicory root - two crucial (but often overlooked) components of the ketogenic diet.

Key Points: 
  • The cornerstone of Premium Jane's new Keto line is a once-a-day fiber supplement formulated with inulin and chicory root - two crucial (but often overlooked) components of the ketogenic diet.
  • "We are beyond thrilled to unveil our new Keto product line," says Premium Jane CEO Jeff Yauck.
  • Additionally, Premium Jane is offering Keto BHB gummies, which contain a unique blend of calcium, magnesium, and sodium beta-hydroxybutyrate (BHB).
  • To place an order or to learn more about the new Keto product range from Premium Jane, visit the company's official website at www.PremiumJane.com .

Diet and nutrition: how well Tanzanians eat depends largely on where they live

Retrieved on: 
Tuesday, April 9, 2024

Across the continent the urban share of the total population is projected to increase to 50% by 2030 and 60% by 2050.

Key Points: 
  • Across the continent the urban share of the total population is projected to increase to 50% by 2030 and 60% by 2050.
  • Urbanisation is associated with lifestyle changes such as less physical activity and less labour-intensive work.
  • This is often accompanied by an increased intake of high-calorie fast foods, snacks, and sugar-sweetened beverages.

Food diaries

  • Using data from food diaries recorded by 1,506 households over a two-week period, I calculated how many calories, macronutrients and micronutrients were consumed and compared them to the recommended requirements for a healthy life.
  • Besides food diaries, our data also included information on household characteristics and their socioeconomic status.

Homegrown or highly processed?

  • This was because they were not eating sufficient quantities of food.
  • Most food was home-grown, which provided beneficial nutrients, but diets were not diverse enough to provide all the nutrients needed for healthy living.
  • At the opposite end of the scale, residents of Dar es Salaam also ate unhealthy diets, but for very different reasons.

Calories, nutrients or a lack thereof

  • Rural households primarily consumed starches, cereals, vegetables and fruit, making up 29%, 21%, 12% and 7% of their diet respectively.
  • Plantains, maize, cassava, sweet potatoes and spinach were the most consumed food items in rural areas.
  • Many of these nutrients are found in animal foods, which made up a small share of rural diets.
  • In terms of quantity, these households tended to consume more, leading to lower levels of nutritional deficiencies than in rural areas.
  • About 26% of households did not meet the recommended calorie intake, but this was significantly better than in rural areas.

Next steps

  • At the same time, overconsumption of potentially harmful food substances such as fats and sugars can lead to health risks such as obesity, diabetes and cardiovascular disease.
  • The findings highlight the need for a varied approach to dealing with nutrient intake and tackling problems such as rising obesity rates.


Hannah Ameye does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Retrieved on: 
Friday, March 22, 2024

In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.

Key Points: 
  • In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.
  • They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
  • NEXLETOL and NEXLIZET are also the first oral non-statin LDL-C lowering drugs to be approved by the FDA to reduce the risk of CV events in both primary and secondary prevention patients.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

Retrieved on: 
Friday, March 22, 2024

ANN ARBOR, Mich. and MUNICH, Germany, March 22, 2024 (GLOBE NEWSWIRE) -- Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) and Esperion Therapeutics, Inc. jointly announced today, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions for the label update of both bempedoic acid (marketed as NILEMDO®▼) and the bempedoic acid / ezetimibe fixed dose combination (FDC) (marketed as NUSTENDI®▼ ), recommending their approval as treatments to reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk.2 The existing label of bempedoic acid (NILEMDO®▼) provides authorisation for adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:2

Key Points: 
  • “We are thrilled with the positive CHMP opinion, which reflects the significant cardiovascular risk reduction benefit that the bempedoic acid global franchise brings to patients worldwide,” said Sheldon Koenig, President and CEO, Esperion.
  • The CHMP is a scientific committee of the EMA that reviews medical product applications on their scientific and clinical merit.
  • Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels which may lead to gout.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

Retrieved on: 
Friday, March 22, 2024

After extensive discussions with metabolic geneticists, dieticians, and PKU patients, we believe PKU GOLIKE is the best product in the estimated $100 million U.S. PKU medical formula market.

Key Points: 
  • After extensive discussions with metabolic geneticists, dieticians, and PKU patients, we believe PKU GOLIKE is the best product in the estimated $100 million U.S. PKU medical formula market.
  • PKU GOLIKE’s taste-masked, odor-free coating technology is designed to provide a better taste and a superior experience compared to alternative PKU medical formulas.
  • Relief launched PKU GOLIKE Granules in the United States in the fourth quarter of 2022 and the PKU GOLIKE Tropical Bar in the second quarter of 2023.
  • Eton plans to promote PKU GOLIKE with its existing metabolic sales force, which currently promotes Eton’s Carglumic Acid, Betaine, and Nitisinone products.

American Kidney Fund Launches Phosphorus Management Education and Awareness Campaign

Retrieved on: 
Tuesday, March 19, 2024

ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced a new patient-focused educational awareness campaign on managing high phosphorus, also known as hyperphosphatemia.

Key Points: 
  • ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced a new patient-focused educational awareness campaign on managing high phosphorus, also known as hyperphosphatemia.
  • AKF’s phosphorus management education campaign will work to raise awareness among dialysis patients about why phosphorus levels matter, ways to manage phosphorus intake with low phosphorus foods and fluids, and information about existing and new phosphate lowering medications, including phosphate blockers.
  • The campaign will provide people with a host of resources, including a patient-facing education page on AKF’s website; a page on AKF’s nutrition website, Kidney Kitchen ®; downloadable guides on talking to your doctor about phosphorus and low phosphorus foods; and a patient-facing session on hyperphosphatemia management at Kidney Action Week 2024 .
  • We hope that this campaign provides much-needed information to patients and families and can make an impact on their disease management.”

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

Retrieved on: 
Tuesday, March 19, 2024

Dr. Allen Davidoff, CEO of XORTX, stated, “2023 marked a year of substantial clinical, technological and regulatory progress, establishing the foundation for the Company’s 2024 goals.

Key Points: 
  • Dr. Allen Davidoff, CEO of XORTX, stated, “2023 marked a year of substantial clinical, technological and regulatory progress, establishing the foundation for the Company’s 2024 goals.
  • Each of these milestones permit the next step in the Company’s clinical development plan, being a “registration” clinical trial – XRX-OXY-201 in pursuit of accelerated approval and support of the Company’s lead program XRx-008 program for ADPKD.
  • Chemistry and Manufacturing, Clinical and Pre-Clinical Highlights – Produced drug substance for oxypurinol production and produced GMP drug substance; confirmed XORLO™ formulation, produced enhanced bioavailability and produced clinical supply of tablets for clinical trials.
  • August 29, 2023 – XORTX submitted an Orphan Drug Designation application to the EMA for the treatment of ADPKD.